|
|
.
See Category: Factors influencing health status and contact with health services
ICD-10 (CM) Code and Descriptor
|
Z11.9 |
Encounter for screening for infectious and parasitic diseases, unspecified
This code is considered unacceptable as a principal diagnosis.
|
Z119 utilizaton on OPPS claims.*
Primary
ICD10 Code |
ICD10
Position 2 |
ICD10
Position 3 |
ICD10
Position 4 |
ICD10
Position 5 |
ICD10
Position 6 |
ICD10
Position 7 |
ICD10
Position 8 |
ICD10
Position 9 |
ICD10
Position 10 |
| 15.59%
|
15.85%
|
12.62%
|
11.25%
|
15.21%
|
9.41%
|
6.44%
|
4.71%
|
2.53%
|
1.75%
|
* Medicare Part A utilization data is derived from the 100% 2023 Outpatient (Fee-for-Service) Standard Analytical File.
Commonly Associated Procedure Codes for Z11.9*:
| CPT |
Description |
Number of Claims |
Sum Performed |
|
U0003
|
COV-19 AMP PRB HGH THRUPUT |
3,470
|
3,471
|
|
U0005
|
INFEC AGEN DETEC AMPLI PROBE |
2,529
|
2,529
|
|
36415
|
COLL VENOUS BLD VENIPUNCTURE |
1,174
|
1,180
|
|
85025
|
COMPLETE CBC W/AUTO DIFF WBC |
620
|
620
|
|
C9803
|
HOPD COVID-19 SPEC COLLECT |
556
|
557
|
|
80053
|
COMPREHEN METABOLIC PANEL |
517
|
517
|
|
80061
|
LIPID PANEL |
495
|
495
|
|
87635
|
SARS-COV-2 COVID-19 AMP PRB |
421
|
421
|
|
83036
|
HEMOGLOBIN GLYCOSYLATED A1C |
408
|
408
|
|
80048
|
METABOLIC PANEL TOTAL CA |
350
|
350
|
|
86803
|
HEPATITIS C AB TEST |
333
|
333
|
|
86769
|
SARS-COV-2 COVID-19 ANTIBODY |
319
|
330
|
|
87081
|
CULTURE SCREEN ONLY |
313
|
314
|
|
86618
|
LYME DISEASE ANTIBODY |
255
|
269
|
|
84443
|
ASSAY THYROID STIM HORMONE |
250
|
250
|
|
U0004
|
COV-19 TEST NON-CDC HGH THRU |
232
|
232
|
|
G0463
|
HOSPITAL OUTPT CLINIC VISIT |
212
|
212
|
|
85027
|
COMPLETE CBC AUTOMATED |
186
|
186
|
|
80076
|
HEPATIC FUNCTION PANEL |
175
|
175
|
|
82550
|
ASSAY OF CK (CPK) |
167
|
167
|
* Derived from 100% 2021 Outpatient (Fee-for-Service) Standard Analytical File.
Z11.9 related to the following DRG Codes:
951
|
